ALMS · Stock Price
Historical price data
Overview
Alumis is a clinical-stage biotech advancing a late-stage portfolio of precision oral therapies for immune-mediated diseases, leveraging a proprietary data analytics platform to de-risk development. The company's lead asset, envudeucitinib, has delivered strong Phase 3 data in plaque psoriasis, potentially positioning it as a best-in-class oral TYK2 inhibitor. With a seasoned leadership team and a $2.91B valuation, Alumis's strategy focuses on bringing its lead program to market while expanding into adjacent immunology indications to build a multi-product company.
Technology Platform
A proprietary precision data analytics platform that integrates multi-omics and clinical data to identify disease drivers, patient subtypes, and de-risk the development of targeted therapies for immune-mediated diseases.
Pipeline
13| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Open-Label ESK-001 + Blinded ESK-001 + Placebo | Plaque Psoriasis | Phase 3 | |
| ESK-001 + Apremilast + Placebo | Plaque Psoriasis | Phase 3 | |
| ESK-001 + Placebo + Apremilast | Plaque Psoriasis | Phase 3 | |
| ESK-001 | Uveitis Posterior Non-Infectious | Phase 2 | |
| ESK-001 | Plaque Psoriasis | Phase 2 |
Funding History
8Opportunities
Risk Factors
Competitive Landscape
Alumis competes directly with Bristol Myers Squibb's approved TYK2 inhibitor, Sotyktu, and a pipeline of next-generation oral TYK2 candidates from rivals like Takeda. The broader competitive set includes highly effective but injectable biologic therapies targeting IL-23 and IL-17, against which envudeucitinib must demonstrate compelling efficacy and convenience.
Company Timeline
IPO — $248.0M
Series F: $259.0M
Series E: $259.0M